All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Secukinumab
Therapeutic Area: Dermatology Product Name: Cosentyx
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial demonstrated significant treatment response of Cosentyx® (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA) versus placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Crizanlizumab
Therapeutic Area: Genetic Disease Product Name: Adakveo
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
Data shows that nine out of ten people living with sickle cell disease experience one or more VOCs in a year, with a third of those crises leading to hospitalization, underscoring the significant unmet need among a vulnerable group of patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV gene therapy
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Recipient: Vedere Bio
Deal Size: $280.0 million Upfront Cash: $150.0 million
Deal Type: Acquisition October 29, 2020
Details:
Acquisition of Vedere Bio includes lead preclinical intravitreally-injected AAV gene therapy programs focused on pan-genotypic vision restoration in patients with photoreceptor-based vision loss.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NIS793,Spartalizumab,Gemcitabine
Therapeutic Area: Oncology Product Name: NIS793
Highest Development Status: Phase II Product Type: Large molecule
Recipient: XOMA
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 28, 2020
Details:
The Phase 2 trial will assess the efficacy and safety of NIS793 in first-line metastatic pancreatic ductal adenocarcinoma. The milestone payment is apart of an agreement signed between Xoma and Novartis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MP0420
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Preclinical Product Type: Large molecule
Recipient: Molecular Partners
Deal Size: $231.0 million Upfront Cash: $22.0 million
Deal Type: Licensing Agreement October 28, 2020
Details:
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Onasemnogene Abeparvovec,NAV AAV9 vector
Therapeutic Area: Genetic Disease Product Name: Zolgensma
Highest Development Status: Approved Product Type: Cell and Gene therapy
Recipient: Regenxbio
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 27, 2020
Details:
REGENXBIO will receive a milestone payment of $80.0 million from Novartis AG based upon the achievement of $1.0 billion in cumulative net sales of Zolgensma. REGENXBIO expects to recognize this revenue in the third quarter of 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Iptacopan
Therapeutic Area: Nephrology Product Name: LNP023
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Data presented at the ASN 2020 Annual Meeting shows that investigational iptacopan effectively and safely reduced proteinuria in patients with C3 glomerulopathy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OP-1250,Ribociclib
Therapeutic Area: Oncology Product Name: OP-1250
Highest Development Status: Undisclosed Product Type: Small molecule
Recipient: Olema Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 26, 2020
Details:
Novartis will evaluate OP-1250 and a selective ER degrader (SERD), in combination with each of Kisqali® (ribociclib) and Piqray® (alpelisib) in patients with recurrent, locally advanced or metastatic estrogen receptor-positive (ER+), HER2 (-) breast cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Iptacopan
Therapeutic Area: Nephrology Product Name: LNP023
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the alternative complement pathway, which is involved in the underlying pathophysiology of IgA nephropathy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Branaplam
Therapeutic Area: Genetic Disease Product Name: LMI070
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
In preclinical models, branaplam has been shown to reduce levels of mutant huntingtin protein. In addition, during the investigation of branaplam in spinal muscular atrophy (SMA), it was also observed to reduce huntingtin messenger RNA (mRNA) in SMA patients.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
